What is Syndax Pharmaceuticals's term loan?

Syndax Pharmaceuticals (SNDX) reported term loan of $0 in Q4 2025.

What does term loan mean?

This represents the portion of bank loans and credit facilities that are due for repayment within the next twelve months. It is a critical measure of the company's short-term debt service obligations and liquidity pressure. Investors use this to evaluate the company's reliance on external financing and its ability to meet immediate debt maturities.

Syndax Pharmaceuticals SNDX Term loan

Term loan at other companies

BlockXYZ

$283.56M—

CorpayCPAY

$2.14B+45.9%

CotyCOTY

$2.1M-77.7%

GeneDx HoldingsWGS

$5.13M+64.2%

PhiniaPHIN

$24M-4.0%

TecnoglassTGLS

$4.34M—

Other financials

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

See full

Market cap$1.74B+95.0%

Enterprise value$1.96B+84.0%

P/S8×-12.4×

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LoansPayableToBankCurrent.

The official record: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's term loan.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's term loan?: Syndax Pharmaceuticals (SNDX) reported term loan of $0 in Q4 2025.
What does term loan mean?: This represents the portion of bank loans and credit facilities that are due for repayment within the next twelve months. It is a critical measure of the company's short-term debt service obligations and liquidity pressure. Investors use this to evaluate the company's reliance on external financing and its ability to meet immediate debt maturities.